ReviewFrontiers in immunology2026
Research advancements in DNA methylation pertaining to ankylosing spondylitis.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ankylosing spondylitis (AS) is a persistent autoimmune disorder marked by inflammation of the spine and sacroiliac joints, along with atypical bone development. In recent years, DNA methylation, a significant epigenetic modification, has become a pivotal element affecting AS pathogenesis, disease progression, and clinical diagnosis. This review summarizes what we know so far about abnormal DNA methylation patterns in AS-related genes like DKK1, ERAP1, PDCD1, FOXO1/3a, LGR6, and IRF5, as well as how these patterns affect gene expression. It examines the interaction between DNA methylation and essential pathological processes such as inflammatory responses, immune regulation, and bone metabolism. Additionally, the prospective utilization of DNA methylation as a biomarker for the diagnosis and prognosis of AS is analyzed. Finally, we talk about new ways to treat AS that focus on DNA methylation mechanisms. This review seeks to amalgamate recent methylome and transcriptome studies to establish a comprehensive theoretical framework and delineate future research directions aimed at elucidating epigenetic mechanisms in AS and promoting clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.